GlassScriptPhysician profile
Maya Janel Simmons
NPI 1689348245
$2,896.46
in general payments reported to CMS, 2019-2025
24 companies · $20.30 in 2025
The $20.30 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $107 · 2022: $367 · 2023: $1,293 · 2024: $1,109 · 2025: $20.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,370 · Education: $53.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,369.67 |
| Education | $53.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $747.24 | 2022-2024 | Tezspire, Fasenra, Airsupra |
| Regeneron Healthcare Solutions, INC. | $545.90 | 2023-2024 | Dupixent |
| Glaxosmithkline, LLC. | $313.87 | 2023-2024 | Trelegy Ellipta, Nucala, Arexvy |
| Biocryst US Sales Co., LLC | $170.52 | 2023-2024 | Orladeyo |
| Bayer Healthcare Pharmaceuticals INC. | $124.49 | 2022 | |
| Abbvie INC. | $101.71 | 2022-2025 | |
| Kaleo, INC. | $92.81 | 2023-2024 | Auvi-Q |
| Amgen INC. | $84.96 | 2023-2024 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $80.33 | 2023 | Takhzyro, Hyqvia |
| Csl Behring | $72.63 | 2023-2024 | Hizentra |
| Lilly USA, LLC | $65.83 | 2021-2022 | |
| Aytu Biopharma, INC. | $60.42 | 2023 | Karbinal |
| Biohaven Pharmaceutical Holding Company LTD. | $56.44 | 2022 | |
| Genentech USA, INC. | $54.73 | 2023-2024 | Xolair |
| Octapharma USA, INC. | $54.20 | 2023-2024 | Cutaquig, Panzyga |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $45.59 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.64 | 2022 | |
| Novo Nordisk INC | $34.65 | 2021-2022 | |
| Incyte Corporation | $34.58 | 2024 | Opzelura |
| Hikma Pharmaceuticals USA | $31.96 | 2023 | Ryaltris |
| Genzyme Corporation | $30.10 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $24.37 | 2021 | |
| Grifols USA, LLC | $20.79 | 2023 | Xembify |
| Tactile Systems Technology INC | $12.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maya Simmons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.